Ovid reports Phase 1 safety and PK for OV350; oral KCC2 activator OV4071 on track for Q1 2026 filing

Ovid Therapeutics Inc.

OV350 IV showed good safety; no treatment-related SAEs or lab findings in 16 healthy participants.
PK as predicted; exploratory qEEG indicated central activity consistent with KCC2 modulation.
OV4071 (oral) is 20-fold more potent; regulatory submission for Phase 1/1b expected Q1 2026, clinical start Q2 2026.
Company will not advance OV350 IV further; resources directed to oral KCC2 activators OV4071 and OV4041.
Most common AE was headache; nausea/vomiting in subset attributed to off-target pharmacology.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.